Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, China.
College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Bioorg Med Chem. 2023 Oct 1;93:117441. doi: 10.1016/j.bmc.2023.117441. Epub 2023 Aug 14.
Targeting sphingosine kinase 2 (SphK2) has become a novel strategy for the treatment of cancer. However, potent and selective SphK2 inhibitors are rare. In our work, a series of novel SphK2 inhibitors were innovatively designed, synthesized and screened. Compound 12e showed the best inhibitory activity. Molecular dynamics simulations were carried out to analyze the detailed interactions between the SphK2 and its inhibitors. Moreover, 12e exhibited anti-proliferative activity in various cancer cells, and inhibited the migration of human breast cancer cells MCF-7.
靶向鞘氨醇激酶 2(SphK2)已成为治疗癌症的一种新策略。然而,高效且选择性的 SphK2 抑制剂却十分罕见。在我们的工作中,创新性地设计、合成并筛选了一系列新型 SphK2 抑制剂。化合物 12e 表现出了最佳的抑制活性。通过分子动力学模拟分析了 SphK2 与其抑制剂之间的详细相互作用。此外,12e 在多种癌细胞中表现出抗增殖活性,并抑制人乳腺癌细胞 MCF-7 的迁移。